A Phase III, Randomised, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of CUV1647 in Patients Suffering From Polymorphic Light Eruption (PLE).
Latest Information Update: 06 May 2017
At a glance
- Drugs Afamelanotide (Primary)
- Indications Polymorphus light eruptions
- Focus Registrational; Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
- 17 Apr 2014 New trial record